Contraindicated for use in CHF patients
- Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Such activity has been shown to decrease survival compared to placebo in patients with class III-IV CHF.
- Contraindicated in patients with CHF of any severity.
Patient Counseling Information
Updated January 2018